Many of the current approaches use monoclonal antibodies (mAbs) or soluble cytokine receptor antagonists to ablate a single cytokine, such as tumor necrosis factor (TNF)α, interleukin (IL)-1, or IL-6, or interfere with a specific T helper cell response (Th1 or Th17) by targeting the cytokines that initiate or are being produced during autoimmune/inflammatory responses in RA. Here, IL6 is linked to rheumatoid arthritis.